ASCO 2025 | Emerging treatment strategies for heavily pretreated CRPC

So I think before combination, the first question with this is if this was to be tested in a phase three setting, should it be tested in an earlier line of treatment? And certainly with this study, we saw that patients who were treated in the second or third line had a much better objective response rate around 58%, although activity was seen across all side groups and all treatment lines. And certainly with a six-month progression-free survival rate of 100% in this line, whether it is used in the second and third line setting, that’s certainly an area which is going to be explored where patients will be tested prior to docetaxel chemotherapy. The other possibility is using it in the post-lutetium 177 setting, which is an area of need where there’s not many good standard of care options now for castration-resistant prostate cancer. And currently, in the phase two setting at least, this will be tested in looking at these two settings in particular. In regards to combination strategies, certainly one of the areas of interest would be looking at combinations with other ARPIs and seeing whether they could see better efficacy in the combination setting without compromising on safety or the other area of interest is immunomodulatory agents as well in combinations but that’s still yet to be developed.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.